Results 161 to 170 of about 109,434 (328)

Passive cellular anaphylaxis [PDF]

, 1917
W. H. Manwaring, Harold E. Crowe
openalex   +1 more source

Personalized Cancer Vaccines in the Clinical Trial Pipeline

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study analyzes the current landscape of personalized cancer vaccine clinical trials, highlighting trends in vaccine platforms, trial phases, and geographic distribution. Peptide and dendritic cell vaccines dominate early‐stage research, with promising immune responses observed in melanoma, glioblastoma, and urothelial cancer trials.
Liudmila Iamukova, Elena Alferova
wiley   +1 more source

Perioperative anaphylaxis: Management and risk reduction strategies in 2024

Journal of Perioperative Nursing
The Australian and New Zealand College of Anaesthetists (ANZCA) reports anaphylaxis is the most common cause of death associated with anaesthesia in Australia, and the incidence is rising.
Mishelle Dehaini
doaj   +1 more source

Maternity Healthcare Worker Perspectives of Severe Acute Maternal Morbidity Recording, Reporting and Case Review in Queensland, Australia

Australian and New Zealand Journal of Obstetrics and Gynaecology, EarlyView.
ABSTRACT Background Systematic, multi‐disciplinary review of Severe Acute Maternal Morbidity (SAMM) can improve maternal outcomes. Routinely collected data, collated into the Queensland SAMM Dashboard, may facilitate local case review. We wanted to understand how SAMMs are reviewed locally and how centrally collated data supports review processes ...
Joanne Frost, Edward Weaver, Leonie Callaway   +2 more
wiley   +1 more source

Dual Inhibition of Mast Cells and Thymic Stromal Lymphopoietin Using a Novel Bispecific Antibody, CDX‐622

Allergy, EarlyView.
SCF and TSLP expression are known to drive unique immune responses leading to the onset of allergic and inflammatory diseases. Here, we describe the characterization of a novel bsAb, CDX‐622, that targets SCF and TSLP. CDX‐622 inhibits MC functions through SCF starvation and Type 2 inflammatory responses via TSLP inhibition.
Michael B. Murphy, Laura Vitale, Thomas O'Neill, Deena M. Maurer, Linda Malenchek, Andrea Crocker, Colleen Patterson, Laura Mills‐Chen, Virginia Saley, Nicole M. Antczak, James M. Boyer, Kelly M. McManus, Noe Rico Montanari, Russell A. Hammond, Joel Goldstein, Lawrence J. Thomas, Tibor Keler, Diego Alvarado   +17 more
wiley   +1 more source

Prevalence, incidence and mortality of anaphylaxis in Colombia

Revista Alergia México, 2018
Background: The lifetime prevalence of anaphylaxis from all triggers is estimated to range from 0.05 % to 2.6 %. Data on anaphylaxis in the Latin American region and Colombia are scant.
Pablo Andrés Miranda-Machado
doaj  

ASTHMA AND ANAPHYLAXIS [PDF]

, 1921
T. M. Allison
openalex   +1 more source

Passive Cutaneous Anaphylaxis in the Mouse [PDF]

, 1958
Zoltán Óváry
openalex   +1 more source

THE PRESENT STATUS OF THE PROBLEMS OF ANAPHYLAXIS [PDF]

, 1921
H. Gideon Wells
openalex   +1 more source

Understanding the Variability of Peanut‐Oral Immunotherapy Responses by Multi‐Omics Profiling of Immune Cells

Allergy, EarlyView.
This study analyzes molecular drivers of OIT responsiveness. Multi‐omics profiling of peanut‐stimulated PBMCs in a controlled peanut‐OIT trial identifies immune, transcriptomic, and epigenetic changes distinguishing complete responders from incomplete responders. Key findings highlight gastrointestinal immune mechanisms, including extracellular exosome
Aleix Arnau‐Soler, Sarah E. Ashley, Ahla Ghauri, Alexander C. S. N. Jeanrenaud, Ingo Marenholz, Katharina Blumchen, Penelope Cibin, Alisa Iakupova, Norbert Hubner, Kirsten Beyer, Young‐Ae Lee   +10 more
wiley   +1 more source